Preliminary results from the phase II WU-KONG trial of sunvozertinib therapy in EGFR ex20ins lung cancer patients have recently been presented, and these demonstrate a high objective response rate of 73.1% in the first-line setting among 26 evaluable patients [15]. This evidence concerns the gene EGFR and lung cancer.